Local reactions and systemic reactions after ID injection of PFE-BNT , antibody response after ID injection of PFE-BNT immunogenicity side effects
Conditions
Interventions
PFE-BNT was prepared under the recommendation of department of disease control, Thailand. Sterile 0.9% of Nacl 1.8 ml is added into PFE-BNT vaccine vial as a diluent. After diluting, each vial contain
Experimental Drug
PFE-BNT Indradermal injection
Sponsors
Lampang Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: participants were adults aged more than 18 years who completed 2 doses of a three-week schedule of Verocell, and have not had SARS-CoV-2 infection.
Exclusion criteria
Exclusion criteria: Participants were excluded from the study if they: had history of severe adverse or allergic reactions to previous vaccinations, were pregnancy or planned pregnancy within 4 weeks after vaccination, used of systemic or topical corticosteroids, had bleeding diathesis , received other Covid-19 vaccine, and had SARS-CoV-2 infection before collecting post ID injection blood sample.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability immediate, 30 minutes, day 1, day 7, and day 30 Direct observe , Vaccine side effect report form | — |
Secondary
| Measure | Time frame |
|---|---|
| Antibody response Before receiving ID injection, at day 30 after ID injection immunoglobulin class G (IgG) antibodies to the receptor binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. | — |
Countries
Thailand
Contacts
Public ContactWachiraporn Arunothong
Lampang Hospital
Outcome results
None listed